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AbstrAct
Introduction: M2-polarized tumor-associated macrophages (TAMs) and TIE2-
expressing monocytes (TEMs) are associated with angiogenesis and have been 
identified as a potential prognostic marker in several solid tumors, including 
hepatobiliary malignancies. However, little is known regarding their influence on 
tumor progression and patient survival in pancreatic ductal adenocarcinoma (PDAC).
Results: Patients with tumors characterized by the presence of CD163+ TAMs or 
TEMs in TCA or TIF, respectively, showed a significantly decreased 1-, 3- and 5-year 
overall and recurrence-free survival compared to patients without CD163+ TAMs or 
TEMs (all ρ < 0.05). Patients with TEMs in TCA showed a higher incidence of tumor 
recurrence (ρ < 0.05). Furthermore, the presence of CD163+ TAMs was associated 
with a higher tumor MVD (ρ < 0.05). 
Conclusions: Presence of M2-polarized TAMs and TEMs is associated with a 
decreased overall and recurrence-free survival of patients with PDAC. 
Materials and methods: The localization and density of CD163+ M2-polarized 
TAMs and TEMs were quantified in the tumor central area (TCA) and tumor-infiltrating 
front (TIF) in human PDAC tissue (n = 106) and correlated to clinicopathological 
characteristics, tumor recurrence rates and patient survival. In parallel, tumor 
microvascular density (MVD) and the density of angiopoietin-positive tumor cells 
were quantified. Statistical analysis was performed using SPSS software.
www.oncotarget.com                               Oncotarget, 2018, Vol. 9, (No. 51), pp: 29715-29726
           Research Paper
Oncotarget29716www.oncotarget.com
IntroductIon
Solid cancers harbor different subpopulations of 
immune cells, each of which has the potential for pro- or 
anti-tumor functions. Macrophages are the predominant 
immune cell population found throughout tumors and 
macrophage numbers or functions can be modulated in 
order to augment anti-cancer therapies [1]. The immune 
activation state of these tumor-associated macrophages 
(TAMs) can be divided into M1- (anti-cancer function) and 
M2-type (pro-tumoral or immunosuppressive) [2]. Various 
escape mechanisms deployed by malignant cells and the 
tumor microenvironment (TME) mediate the conversion 
of infiltrating macrophages into immunosuppressive and 
pro-tumoral M2 TAMs [3]. Therefore, understanding and 
targeting the specific pathways associated with the M2 
polarization state of TAMs is a promising approach for 
therapeutic strategies.
As previously reported by us, a differential influence 
and functionality of localized tumor sites in TME, i.e. 
tumor central area (TCA) and tumor invasive front (TIF), 
on related immunologic responses play a key role in cancer 
immunity and tumor progression [4]. TAMs localized 
in TCA or TIF can impact oncogenesis in an opposite 
manner. High TAMs frequency in TCA is associated 
with poor prognosis in hepatocellular carcinoma (HCC), 
esophageal, ovarian and breast cancer [5–10]. By contrast, 
TAMs in TIF in colonic, gastric, and endometrial cancer 
correlate with a favorable outcome [11–13]. TME, tumor-
derived factors and escape mechanisms facilitate tumor 
growth, neovascularization, and metastasis. However, a 
constant interplay between immune responses in TCA or 
TIF and infiltrating TAMs and their polarization states, 
plays a key role in this process.
Tumor angiogenesis is a major factor in the 
development and progression of cancer and therefore 
inhibiting it is a promising therapeutic target [14]. Members 
of the angiopoietin (Ang) family are potent growth factors 
and important modulators of tumor angiogenesis but could 
represent functional antagonists as well [15]. Monocytes/
macrophages are primary producers of angiogenic mediators 
in oncogenesis [16–17]. Bone marrow (BM)-derived 
myeloid cells contribute significantly to tumor angiogenesis 
[18]. In both mice and humans, a subset of proangiogenic 
circulating and tumor-infiltrating monocytes expressing 
functionally active Ang receptor TIE2 have been recently 
identified [19]. These Tie2-expressing monocytes (TEMs) 
are selectively recruited to tumors, foster neoangiogenesis, 
and oncogenesis, but are not found in non-cancerous tissues 
[20, 21]. We have previously demonstrated that in respect to 
tumor vascularization grade, monocyte localization in TCA 
or TIF and related cancer immunity, these tumor-infiltrating 
TEMs and TAMs can impact survival and prognosis in an 
opposite manner [4, 22, 23]. 
Clinical significance of angiogenic TEMs and M2-
polarization state of infiltrating TAMs has been suggested 
for human malignancies, where the interplay between tumor 
immunology and angiogenesis plays a key role in oncogenesis 
[20]. Recently, we showed that tumor Ang density, 
corresponding angiogenic TEMs and infiltrating TAMs 
impact patent survival and exert prognostic significance 
in primary hepatic tumors and hilar cholangiocarcinomas 
[4, 22, 23]. However, the importance of these immune 
markers in pancreatic ductal adenocarcinoma (PDAC) is 
unknown. The aim of this study was therefore to evaluate 
the importance of M2-polarized TAMs, Angs and related 
Ang-receptor bearing TEMs and their association with 
tumor angiogenesis, tumor growth, metastasis, recurrence 
and clinical prognosis in human PDAC.
rEsuLts
The overall 1-, 3- and 5-year survival of our cohort 
was 81.2, 44.9 and 41.8%, respectively. The recurrence-
free 1-, 3- and 5- year survival rates were 75.7, 45.1 and 
43.9%, respectively. Sixty-four out of the 106 (64/106, 
60.4%) patients died within the follow-up interval. In 
52/106 patients (49.1%) tumor recurrence was diagnosed 
and 40/106 (37.7%) patients died of recurrent disease. 
Local tumor recurrence was detected in 20/106 (18.9%) 
patients. In 50/106 (45.9%) patients distant metastases 
were seen (Table 1). 15/106 (14.1%) patients had a local 
recurrence and metastatic disease. Nineteen/106 (17.9%) 
patients died from other causes and had no signs of tumor 
recurrence at the time of death.
tEMs, tAMs and angiopoietin distribution in 
PdAc
Typical images for the tissue distribution of TEMs, 
CD68+ or CD163+ TAMs and angiopoietins are shown in 
Figure 1A–1H, the respective statistical evaluation of all 
patients is summarized in Tables 2, 3 and 4. TEMs are 
preferentially located in areas of tumor neovascularization, 
but not in tumor necrosis regions (Figure 1A–1B). CD68+ 
or CD163+ TAMs showed a uniform density in the tumor 
stroma, TCA, TIF and were also present in necrotic tumor 
regions (Figure 1C–1D). The pattern of TEMs and CD163+ 
TAMs displayed a preference for the tumor perivascular 
areas (Figure 1A). High Ang density (Figure 1E–1F) was 
not frequently observed in PDAC, as most cases showed 
Ang low abundance. In contrast, most of PDAC samples 
displayed high tumor microvascular density (MVD) 
(Figure 1G–1H). 
tEMs associate with metastatic disease and 
tumor recurrence in PdAc
The presence of TEMs in the TCA was associated 
with an enhanced incidence of metastatic disease (Figure 
1A–1B, Tables 2 and 4). In the TEM+ group 6/7 (85.7%) 
and in the TEM- group 41/99 (41.4%) patients had 
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distant metastases (ρ = 0.023). Interestingly, a significant 
association between infiltrating TEMs and presence of 
hepatic metastases was observed: 76/99 (76.8%) patients 
of the TEM− group had no distant metastases in the liver 
(ρ = 0.047). The presence of TEMs did not correlate to 
other clinicopathologic parameters or to Ang expression 
in PDAC. The frequency of CD68+ TAMs in TCA or TIF 
was not associated with the studied parameters. 
M2-polarized tAMs associate with enhanced 
tumor neovascularization in PdAc 
The presence of CD163+ TAMs in TIF was 
associated with the MVD (Tables 3 and 4). In the CD163+ 
TAM+ group 19/23 (82.6%) patients, whereas in the 
CD163+ TAM– group only 24/59 (47.0%) patients showed 
MVDhigh (ρ = 0.046). Interestingly, TEMs in TCA and 
table 1: clinicopathological characteristics of the patients included in the study
clinicopathological characteristics
Variable Value (%)
No. of patients 106
Gender
 Female 41 (38.7%)
 Male 65 (61.3%)
Patient age
 ≤60 55 (51.9%)
 >60 51 (48.1%)
Pathologic T stage
 T1/T2 22 (20.8%)
 T3/T4 84 (79.2%)
Pathologic N stage
 Positive 32 (30.2%)
 Negative 74 (69.8%)
Lymphangiosis carcinomatosa
 Positive 23 (21.7%)
 Negative 83 (78.3%)
Angionvasion
 Positive 29  (74.5%)
 Negative 27  (25.5%)
Perineural sheath infiltration
 Positive 35 (33.0%)
 Negative 71 (67.0%)
Pathologic R-Category
 R0 82 (77.4%)
 R1/R2 24 (22.6%)
Histologic differentiation  
 Well     4 (3.8%)
 Moderate/Poor 102 (96.2%)
Distant metastases
 With 47 (44.3%)
 Without 59 (55.7%)
Liver metastases
 With 27 (25.5%)
 Without 79 (74.5%)
Tumor recurrence
 With 52 (49.1%)
 Without 54 (50.9%)
Local recurrence
 With 20 (18.9%)
 Without 86 (81.1%)
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table 2: correlation of tIE2-expressing monocytes in tumor central area with clinicopathological characteristics of 
pancreatic adenocarcinoma
clinicopathological analysis
Variable tEMs pos tEMs neg p
No. of patients 7 99
Gender 0.570
 Female 2 (21.6%) 39 (39.4%)
 Male 5 (71.4%) 60 (60.6%)
Patient age, years 0.621 
 >60 4 (57.1%) 47 (47.5%)
 ≤60 3 (42.9%) 52 (52.2%)
Pathologic T stage 0.662
 T1/T2 1 (14.3%) 21 (21.2%)
 T3/T4 6 (85.7%) 78 (78.8%)
Pathologic N stage 0.072
 Positive  0  (00.0%) 32 (32.3%)
 Negative  7  (100.0%) 67 (67.7%)
Lymphangiosis carcinomatosa 0.150
 Positive 0  (00.0%) 23 (23.2%)
 Negative  7  (100.0%) 76 (76.8%)
Angioinvasion 0.482
 With 6 (85.7%) 73 (73.7%)
 Without 1 (14.3%) 26 (26.3%)
Perineural sheath infiltration 0.796
 Positive 2 (28.6%) 33 (33.3%)
 Negative 5 (71.4%) 66 (66.7%)
Pathologic R-category 0.585
 R0 6 (85.7%) 76 (76.8%)
 R1/R2 1 (14.3%) 23 (23.2%)
Histologic differentiation 0.588
 Well 0  (00.0%) 4   (4.0%)
 Moderate/poor 7  (100.0%) 95 (96.0%)
Distant metastases 0.023
 With 6 (85.7%) 41 (41.4%)
 Without 1 (14.3%) 58 (58.6%)
Liver metastases 0.047
 With 4 (57.1%) 23 (23.2%)
 Without 3 (42.9%) 76 (76.8%)
Tumor recurrence 0.045
 With 6 (85.7%) 46 (46.5%)
 Without 1 (14.3%) 53 (53.5%)
Local recurrence 0.093
 With 3 (42.9%) 17 (17.2%)
 Without 4 (57.1%) 82 (82.8%)
MVD 0.255
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CD163+ TAMs in TIF were strongly associated: in the TIF 
CD163+ TAM− group 56/59 (98.2%) patients were TEM-, 
whereas 17/23 (77.3%) patients in the TIF CD163+ TAM+ 
group were TEM+ in the TCA (ρ = 0.002).
Angiopoietin-2 expression associates with 
perineural sheet infiltration in PDAC
Ang-2 expression in TCA correlated with the 
incidence of perineural sheet infiltration (ρ = 0.002) 
(Figure 1E–1F, Table 4). In the ANG2low group, only 20/80 
(25.0%) patients showed a perineural sheet infiltration, 
whereas in the ANG2high group 11/26 (42.3%) patients 
had this phenomenon.  Ang-1 expression in TCA was 
associated inversely with perineural sheet infiltration 
(ρ = 0.038): in the ANG1high group, 31/39 (79.5%) had no 
perineural sheet infiltration.
 Influence of TIE2-expressing monocytes and 
M2-polarized macrophages on survival in PdAc
Patient survival was decreased in patients with 
CD163+ TAMs in TCA (p = 0.041) or TIF (p = 0.021) 
when compared to patients without these cells in both 
tumor sites. The overall 1-, 3- and 5-year survival rates 
were 100, 84.3 and 84.3% in patients of the CD163+ 
TAM- group compared to 76.2, 45.1 and 39.9% in the 
CD163+ TAM+ group, respectively, when considering the 
TIF (Figure 2A) or TCA (data not shown). Furthermore, 
the absence of CD163+ TAMs in TIF correlated with an 
improved recurrence-free survival. The 1-, 3-, and 5-year 
recurrence-free survival of patients without CD163+ TAMs 
were higher (82.4, 53.2, and 53.2%) compared to patients 
with CD163+ TAMs (58.1, 43.7, and 37.6%), respectively 
(p = 0.022; Figure 2B). 
The 1-, 3-, and 5-year recurrence-free survival of 
patients without TEMs in TCA (77.6, 51.8 and 49.9%) 
were higher compared to patients with TEMs (42.9, 21.7 
and 21.7%), respectively (p = 0.012; Figure 2C).  The 
presence of CD68+ TAMs was not associated with patient 
survival (data not shown).
dIscussIon 
Analyzing tissue density of infiltrating M2-polarized 
TAMs, TEMs, and Angs in tumor samples from patients 
who underwent resection for PDAC, we demonstrated 
that (1.) Ang density associates with perineural sheet 
infiltration (2.) angiogenic TEMs and M2-polarized TAMs 
are differentially expressed in PDAC, (3.) correlate with 
metastatic spread and tumor recurrence, (4.) associate with 
angiogenesis, and (5.) impact survival rates. 
The mechanisms that enable solid cancers to escape 
elimination by the immune system remain unclear, 
but their elucidation may provide novel therapeutic 
interventions. Host immune function in TME, i.e. TCA and 
TIF, is shaped by tissue-specific and tumor-derived signals 
that reduce the potency of anti-tumor immune competence. 
This is particularly relevant in human oncogenesis where 
immune tumor infiltration with macrophage/monocyte 
subsets heavily affects prognosis [24]. M2 TAMs and 
TEMs express functional receptors of angiogenesis, 
build up to 50% of the tumor volume, exert a significant 
impact on cancer-related inflammation and angiogenesis, 
inhibit anti-tumor response, and facilitate tumor escape 
mechanisms, metastasis and tumor progression [25]. 
There is a scarce amount of data on the presence 
of TEMs and their correlation with clinicopathologic 
characteristics in human tumors. Furthermore, the 
significance of TEMs to date is established mainly regarding 
their circulating population in human blood [26, 27]. The 
few published studies failed to demonstrate a prognostic 
value of infiltrating TEMs in solid cancerous tissue. To 
our knowledge, the presented work is the first to document 
TEMs presence and importance in PDAC. Intratumoral 
visualization of TEMs using immunoreactivity revealed 
abundance in TCA and TIF, and a preferential localization in 
proximity to microvasculature, as well. Of note, as reported 
by us previously for other human cancers, a considerable 
amount of PDAC samples exhibited an absence of TEMs in 
solid cancerous tissue [23]. 
In our work presence of TEMs and M2 TAMs 
impacted patient survival after resection of PDAC. 
 High 6 (85.7%) 64 (64.6%)
 Low 1 (14.3%) 35 (35.4%)
CD163-positive        0.002
TAMs in TIF
 Positive 1 (50.0%) 56 (36.0%)
 Negative 5 (50.0%) 17 (64.0%)
 CD68-positive 0.480
TAMs in TCA
 Positive 4 (57.1%) 43 (43.4%)
 Negative 3 (42.9%) 56 (56.6%)
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table 3: correlation of cd163-positive tAMs in the tumor invasive front with clinicopathological characteristics of 
pancreatic adenocarcinoma
clinicopathological analysis
Variable cd163 pos cd163 neg p
No. of patients 23   59
Gender 0.127
 Female 12 (52.2%) 20 (33.9%)
 Male 11 (47.8%) 39 (66.1%)
Patient age, years 0.817 
 >60 10 (43.5%) 24 (40.7%)
 ≤60 13 (56.5%) 35 (59.3%)
Pathologic T stage 0.254
 T1/T2 6 (26.1%) 9 (15.3%)
 T3/T4 17 (73.9%) 50 (84.7%)
Pathologic N stage 0.495
 Positive  6 (26.1%) 20 (33.9%)
 Negative  17 (73.9%) 39 (66.1%)
Lymphangiosis carcinomatosa 0.284
 Positive 3 (13.0%) 14 (23.7%)
 Negative  20 (87.0%) 45 (76.3%)
Angioinvasion 0.123
 With 21 (91.3%) 45 (76.3%)
 Without 2 (8.7%) 14 (23.7%)
Perineural sheath infiltration 0.178
 Positive 5 (21.7%) 22 (37.3%)
 Negative 18 (78.3%) 37 (62.7%)
Pathologic R-category 0.641
 R0 19 (82.6%) 46 (78.0%)
 R1/R2 4 (17.4%) 13 (22.0%)
Histologic differentiation 0.271
 Well 0 (0.0%) 3 (5.1%)
 Moderate/poor 23 (100.0%) 56 (94.9%)
Distant metastases 0.074
 With 14 (60.9%) 23 (39.0%)
 Without 9 (39.1%) 36 (61.0%)
Liver metastases 0.052
 With 9 (39.1%) 11 (18.6%)
 Without 14 (60.9%) 48 (81.4%)
Tumor recurrence 0.085
 With 15 (65.2%) 26 (44.1%)
 Without 8 (34.8%) 33 (55.9%)
Local recurrence 0.977
 With 5 (21.7%) 13 (22.0%)
 Without 18 (78.3%) 46 (78.0%)
MVD 0.046
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Multivariate analysis showed that tumor recurrence is 
an independent predictive factor for survival in patients 
with resectable PDAC (data not shown). Therefore, 
the positive correlation between infiltrating TEMs and 
recurrent disease supports the notion that TEMs may be 
a prognostic marker in patients with PDAC. In support of 
this, we found that patients with a higher TEMs frequency 
are at a greater risk of developing metastatic disease and 
especially liver metastases. Of note, the latter usually 
precludes curative surgery and in these cases patients are 
treated with systemic therapy for disease control. Taken 
together, these data implicate the potential use of TEMs 
and CD163+ TAMs as possible biomarkers in PDAC that 
could help deliver more individualized diagnostic and 
therapeutic modalities.
Members of the Ang family of angiogenic 
growth factors are potent regulators of blood- and 
lymphangiogenesis [28]. In agreement with previous 
reports, delineating a negative impact of Ang-2 in PDAC, in 
the current work Ang-2 frequency associated with increased 
incidence of perineural sheet infiltration [29]. However, we 
have previously shown Ang-1 to be associated beneficial 
tumor characteristics in other hepatobiliary malignancies 
[23]. In line with this, in the current work Ang-1 distribution 
revealed an inverse correlation with incidence of perineural 
sheet infiltration. Taken together our data is in concordance 
with published results indicating functional antagonism 
within the human angiopoietin axis. 
The descriptive nature of the presented results 
represents a limitation of the current work. Thus, 
 High 4 (17.4%) 24 (40.7%)
 Low 19 (82.6%) 35 (59.3%)
CD68-positive 0.480
TAMs in TCA
 Positive 15 (65.2%) 41 (71.9%)
 Negative 8 (34.8%) 16 (28.1%)
table 4: Patient groups and scoring in patients with pancreatic adenocarcinoma (n = 106)












angiopoetin-2 determination of angiopoetin-2 in 
tumor cells
TCA ANG2high





CD14, TIE2 determination of TEMs  TCA
positive/presence of TEMs (in 
short: TEM+)
n = 99
negative/absence of TEMs (in 
short: TEM−)
n = 7
CD31 determination of tumor MVD
area of highest 
MVD, “vascular 
hot spot”
MVDhigh (≥50 microvessels/10 
optical fields)
n = 69
MVDlow (<50 microvessels/10 
optical fields)
n = 37
CD68 determination of TAMs TIF
positive/presence of CD68+ 
TAMs (in short: CD68+ TAM+)
n = 73
negative/absence of CD68+ 
TAMs
(in short: CD68+ TAM−)
n = 9
CD163 M2-polaryzation of TAMs TIF
positive/presence of CD163+  
TAMs (in short: CD163+ TAM+)
n = 23
negative/absence of  CD163+  
TAMs
(in short: CD163+ TAM−)
n = 59
Abbreviations: MVD: microvascular density; TAM: tumor associated macrophage; TCA: tumor central area; TEM: Tie2-
expressing monocyte; TIF: tumor infiltrating front.
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functional tests, such as in vitro co-culturing of TEMs and 
tumor-derived factors/tumor cells to measure and verify 
M2-related phenotype and responses will allow a greater 
understanding of this proposed interaction. This could help 
deliver novel strategies for adjunct treatments to augment 
the efficacy of checkpoint blockade inhibitors or more 
standard chemotherapies, radiation, and surgery.
In summary, in the current work M2-polarized TAMs, 
related angiopoietin-axis and corresponding Ang-receptor 
bearing TEMs associated with established clinicopathologic 
Figure 1: Immunohistological detection of angiopoietins and infiltrating monocytes/macrophages (left column: 
high density; right column: low density) in tcA of PdAc specimens. Arrows indicate positive staining, asterisks indicate 
microvessels. Scale bar 50 µm. (A): High density of TIE2+ monocytes in the tumor central areas (TCA). PDAC revealed a homogenous 
infiltration pattern of these cells with preference for the perivascular areas. (b): Low density of TIE2+ monocytes (arrows). (c): High 
density of CD163+ TAMs. (d): Low density of CD163+ TAMs. (E) High Ang-2 expression. (F): Low Ang-2 expression. (G): CD31+- 
microvessels (high microvascular density, high MVD. (H): Low MVD. 
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characteristics and survival in human PDAC. Consequently, 
further research is required to investigate molecular 
mechanisms linking cancer immunity to TEMs functions, 
phenotype and polarization state.
MAtErIALs And MEtHods
Patients and tumor samples 
A total of 106 patients who underwent major 
pancreatectomy for pancreatic adenocarcinoma at the 
Department of Visceral-, Transplantation-, Thoracic- and 
Vascular Surgery, University Hospital Leipzig, Leipzig, 
Germany were included in the study. Adenocarcinoma 
of the pancreas was confirmed histopathologically and 
classified according to the Union for International Cancer 
Control (UICC) classification. This study was carried 
out in accordance with the recommendations of the 
Ethics Committee of the Medical Faculty of the Leipzig 
University (no. 234-14-14072014). 
In all patients, pancreas resection was with curative 
intent and none of the patients received neoadjuvant radio- 
and/or chemotherapy prior to surgery. None of the patients 
died in the postoperative period. Tissue blocks embedding 
a representative sample of the tumor were retrieved 
from the files of the Institute of Pathology. Histological 
diagnosis of the primary tumor stage and nodal status 
were determined by hematoxylin and eosin (H&E) 
stained sections. Histological evaluation of all specimens 
was performed by two investigators (CP and GA) with 
formal training in histopathology, and an independent 
pathologist (KS), without any knowledge of prognosis 
or clinicopathological variables. Paraffin-embedded, 
formalin-fixed tumor samples were used.
Immunohistology
Protocols for immunohistology and quantification 
of cellular infiltrates in paraffin-embedded, formalin-fixed 
tissue samples have been published previously [4, 22, 23]. 
Table 5 summarizes the antibodies and staining conditions 
used. Briefly, 5 µm tumor sections were dewaxed and 
rehydrated. After antigen retrieval and blocking of the 
endogenous peroxidase or alkaline phosphatase activity, 
the sections were consecutively incubated with the primary 
and enzyme-labeled secondary antibody and the respective 
Figure 2: Survival after surgery for PDAC referred to tumor infiltrating monocytes/macrophages. (A) Overall survival 
after surgery for PDAC referred to presence or absence of CD163+ TAMs in the tumor infiltration front (TIF). (b) Recurrence-free survival 
after surgery for PDAC referred to presence or absence of CD163+ TAMs in TIF. (c) Recurrence-free survival after surgery for PDAC 
referred to presence or absence of TEMs in the tumor central area (TCA).
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enzymatic substrate. Sections were counterstained with 
hematoxylin. Specificity controls were performed without 
the primary antibody. 
Density quantification of cellular infiltrates, 
angiopoietins and tumor microvascular density
To quantify TEMs, the sections were double 
immunostained for CD14 and TIE2 [20]. Staining of CD68 
and CD163 was used to quantify TAMs or M2-polarized 
TAMs, respectively. Sections were stained for angiopoietin-1 
and angiopoietin-2 to estimate their expression in tumor 
cells. After immunostaining, the whole tumor area was 
thoroughly inspected for the presence of antibody-positive 
cells. Infiltrating immune cells and angiopoietin-positive 
tumor cells were categorized as negative/absent in up to 5% 
positive cells (0–5% positive cells, score 0) and positive/
present (> 5% positive cells, score 1). Subsequently, patients 
were divided into two groups either to be negative or positive 
for TEMs, CD68+ or CD163+ TAMs, and angiopoietin-1 
or -2+ tumor cells (Table 4). TIF could be microscopically 
visualized in 82 out of 106 (82/106) patients.
Microvessels were identified by CD31 expression. 
Quantification of CD31+ microvessels was performed as 
described [30]. Briefly, the area of highest MVD, that is 
the vascular hot spot, was located by scanning the whole 
tumor section. All microvessels were counted in this spot. 
MVD was calculated from the number of vessels in ten 
random optical fields/section. MVD was categorized 
as low or high (MVDlow and MVDhigh; cut-off value: 50 
microvessels/10 optical fields, Table 4). 
statistical analysis
Survival analysis, univariate analysis and 
Kaplan–Meier curves were generated with the SPSS 
software program (Version 23.0.0.0/Year 2015). 
Comparison of categorical and continuous variables 
was performed using the Chi2-test and the Wilcoxon-
test, respectively. Survival data were compared with 
the log-rank-test. Variables with a significant influence 
on survival in the univariate analysis were entered into 
a Cox regression analysis. A difference was considered 
significant for p < 0.05. 
table 5: Antibodies used for immunostaining
Antigen m/p clone species company secondary antibody company substrate
antigen 
retrieval





































Vector DAB Tris/EDTA 
pH 9.0
CD68 m PG-M1 mouse Agilent
anti-mouse-Ig/ 
peroxidase
Vector DAB Tris/EDTA 
pH 9.0






















Abbreviations: AP: alkaline phosphatase; DAB: 3,3’-diaminobenzidine; m:monoclonal; MVD: microvessel density p: 
polyclonal; TAM: tumor associated macrophage; TEM: Tie2-expressing monocyte.
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Abbreviations
Ang: angiopoietin; DAMP: damage associated 
molecular patterns; HCC: hepatocellular carcinoma; H&E: 
hematoxylin and eosin; mAb: monoclonal antibody; TAM: 
tumor associated macrophage; TCA: tumor central area; 
TEM: Tie2-expressing monocytes; TIF: tumor infiltrating 
front; TME: tumor microenvironment; UICC: Union for 
International Cancer Control; VEGF: vascular endothelial 
growth factor.
Author contributions
Georgi Atanasov: Significant contributions to the 
conception of the study, to the generation, analysis, and 
interpretation of the data, and to preparing the manuscript. 
Charlotte Pötner: Significant contributions to the 
generation and analysis of the data, and to preparing 
the manuscript. Gabriela Aust: critical review of the 
manuscript, resources. Katrin Schierle: Significant 
contributions to analysis and interpretation of the data, and 
to preparing the manuscript. Corinna Dietel: Significant 
contributions to the generation and analysis of the data, 
and to preparing the manuscript. Christian Benzing: 
Significant contributions to conception of the study and 
to preparing the manuscript. Felix Krenzien: Significant 
contributions to conception of the study and to preparing 
the manuscript. Michael Bartels: Significant contributions 
to preparing the manuscript. Uwe Eichfeld: Significant 
contributions to preparing the manuscript. Moritz 
Schmelzle: Significant contributions to the conception of 
the study, to the analysis and interpretation of the data, and 
to preparing the manuscript. Marcus Bahra: Significant 
contributions to preparing the manuscript. Andreas 
Pascher: Significant contributions to preparing the 
manuscript. Georg Wiltberger: Significant contributions to 
the conception of the study, to the generation, analysis and 
interpretation of the data, and to preparing the manuscript.
AcKnoWLEdGMEnts
The authors are most grateful to Dr. Kiruthikah 
Thillai (Cancer Studies, King’s College London, UK, and 
UK Department of Medical Oncology, Guy’s & St Thomas’ 
NHS Trust, London, UK) for the essential collegial support 
and reviewing the manuscript as native speaker.
conFLIcts oF IntErEst
The authors declare that they have no competing 
interests related to the work. 
FundInG
The work presented in this paper was made possible 
by funding from the Berlin Institute of Health (BIH) to GA 
and from the German Federal Ministry of Education and 
Research (BMBF 1315883) to MS. Georgi Atanasov is 
participant of the BIH Charité Clinician Scientist Program 
funded by the Charité/Universitätsmedizin Berlin and the 
Berlin Institute of Health.
rEFErEncEs
 1. Murray PJ. Nonresolving macrophage-mediated 
inflammation in malignancy. FEBS J. 2018; 285:641–653.
 2. Genard G, Lucas S, Michiels C. Reprogramming of Tumor-
Associated Macrophages with Anticancer Therapies: 
Radiotherapy versus Chemo- and Immunotherapies. 
Front Immunol. 2017; 8:828. https://doi.org/10.3389/
fimmu.2017.00828. 
 3. Allard B, Longhi MS, Robson SC, Stagg J. The 
ectonucleotidases CD39 and CD73: novel checkpoint 
inhibitor targets. Immunol Rev. 2017; 276:121–44. https://
doi.org/10.1111/imr.12528. 
 4. Atanasov G, Dietel C, Feldbrügge L, Benzing C, 
Krenzien F, Brandl A, Mann E, Englisch JP, Schierle K, 
Robson SC, Splith K, Morgul MH, Reutzel-Selke A, et 
al. Tumor necrosis and infiltrating macrophages predict 
survival after curative resection for cholangiocarcinoma. 
OncoImmunology. 2017; 6:e1331806. https://doi.org/10.1
080/2162402X.2017.1331806. 
 5. An T, Sood U, Pietruk T, Cummings G, Hashimoto 
K, Crissman JD. In situ quantitation of inflammatory 
mononuclear cells in ductal infiltrating breast carcinoma. 
Relation to prognostic parameters. Am J Pathol. 1987; 
128:52–60. 
 6. Bingle L, Brown NJ, Lewis CE. The role of tumour-
associated macrophages in tumour progression: implications 
for new anticancer therapies. J Pathol. 2002; 196:254–65. 
https://doi.org/10.1002/path.1027. 
 7. Mantovani A, Allavena P, Sica A. Tumour-associated 
macrophages as a prototypic type II polarised phagocyte 
population: role in tumour progression. Eur J Cancer. 2004; 
40:1660–67. https://doi.org/10.1016/j.ejca.2004.03.016. 
 8. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. 
Macrophage infiltration and its prognostic implications in 
breast cancer: the relationship with VEGF expression and 
microvessel density. Oncol Rep. 2005; 14:425–31. 
 9. Condeelis J, Pollard JW. Macrophages: obligate partners for 
tumor cell migration, invasion, and metastasis. Cell. 2006; 
124:263–66. https://doi.org/10.1016/j.cell.2006.01.007. 
10. Pollard JW. Macrophages define the invasive 
microenvironment in breast cancer. J Leukoc Biol. 2008; 
84:623–30. https://doi.org/10.1189/jlb.1107762. 
11. Ohno S, Inagawa H, Dhar DK, Fujii T, Ueda S, Tachibana 
M, Suzuki N, Inoue M, Soma G, Nagasue N. The degree 
of macrophage infiltration into the cancer cell nest is a 
significant predictor of survival in gastric cancer patients. 
Anticancer Res. 2003; 23:5015–22. 
Oncotarget29726www.oncotarget.com
12. Forssell J, Oberg A, Henriksson ML, Stenling R, Jung A, 
Palmqvist R. High macrophage infiltration along the 
tumor front correlates with improved survival in colon 
cancer. Clin Cancer Res. 2007; 13:1472–79. https://doi.
org/10.1158/1078-0432.CCR-06-2073. 
13. Ohno S, Ohno Y, Suzuki N, Kamei T, Koike K, Inagawa H, 
Kohchi C, Soma G, Inoue M. Correlation of histological 
localization of tumor-associated macrophages with 
clinicopathological features in endometrial cancer. 
Anticancer Res. 2004; 24:3335–42. 
14. Wang J, Chen J, Guo Y, Wang B, Chu H. Strategies targeting 
angiogenesis in advanced non-small cell lung cancer. 
Oncotarget. 2017; 8:53854–72. https://doi.org/10.18632/
oncotarget.17957.
15. Balkwill F, Charles KA, Mantovani A. Smoldering and 
polarized inflammation in the initiation and promotion of 
malignant disease. Cancer Cell. 2005; 7:211–17. https://doi.
org/10.1016/j.ccr.2005.02.013. 
16. Hashimoto E, Kage K, Ogita T, Nakaoka T, Matsuoka R, 
Kira Y. Adenosine as an endogenous mediator of hypoxia 
for induction of vascular endothelial growth factor mRNA 
in U-937 cells. Biochem Biophys Res Commun. 1994; 
204:318–24. https://doi.org/10.1006/bbrc.1994.2462. 
17. Semenza GL. Angiogenesis in ischemic and neoplastic 
disorders. Annu Rev Med. 2003; 54:17–28. https://doi.
org/10.1146/annurev.med.54.101601.152418. 
18. De Palma M, Murdoch C, Venneri MA, Naldini L, Lewis 
CE. Tie2-expressing monocytes: regulation of tumor 
angiogenesis and therapeutic implications. Trends Immunol. 
2007; 28:519–24. https://doi.org/10.1016/j.it.2007.09.004. 
19. De Palma M, Venneri MA, Roca C, Naldini L. Targeting 
exogenous genes to tumor angiogenesis by transplantation 
of genetically modified hematopoietic stem cells. Nat Med. 
2003; 9:789–95. https://doi.org/10.1038/nm871. 
20. Venneri MA, De Palma M, Ponzoni M, Pucci F, Scielzo C, 
Zonari E, Mazzieri R, Doglioni C, Naldini L. Identification 
of proangiogenic TIE2-expressing monocytes (TEMs) in 
human peripheral blood and cancer. Blood. 2007; 109:5276–
85. https://doi.org/10.1182/blood-2006-10-053504. 
21. van der Bij GJ, Bögels M, Oosterling SJ, Kroon J, Schuckmann 
DT, de Vries HE, Meijer S, Beelen RH, van Egmond M. 
Tumor infiltrating macrophages reduce development of 
peritoneal colorectal carcinoma metastases. Cancer Lett. 2008; 
262:77–86. https://doi.org/10.1016/j.canlet.2007.11.040. 
22. Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien 
F, Brandl A, Wiltberger G, Matia I, Prager I, Schierle 
K, Robson SC, Reutzel-Selke A, Pratschke J, et al. 
Prognostic significance of macrophage invasion in hilar 
cholangiocarcinoma. BMC Cancer. 2015; 15:790. https://
doi.org/10.1186/s12885-015-1795-7. 
23. Atanasov G, Hau HM, Dietel C, Benzing C, Krenzien F, 
Brandl A, Englisch JP, Wiltberger G, Schierle K, Robson 
SC, Reutzel-Selke A, Jonas S, Pascher A, et al. Prognostic 
significance of TIE2-expressing monocytes in hilar 
cholangiocarcinoma. J Surg Oncol. 2016; 114:91–98. 
https://doi.org/10.1002/jso.24249. 
24. Tacke F. Targeting hepatic macrophages to treat liver 
diseases. J Hepatol. 2017; 66:1300–12. https://doi.
org/10.1016/j.jhep.2017.02.026. 
25. Coussens LM, Werb Z. Inflammation and cancer. Nature. 
2002; 420:860–67. https://doi.org/10.1038/nature01322. 
26. de Visser KE, Eichten A, Coussens LM. Paradoxical roles 
of the immune system during cancer development. Nat Rev 
Cancer. 2006; 6:24–37. https://doi.org/10.1038/nrc1782. 
27. Crawford M, Brawner E, Batte K, Yu L, Hunter MG, 
Otterson GA, Nuovo G, Marsh CB, Nana-Sinkam SP. 
MicroRNA-126 inhibits invasion in non-small cell lung 
carcinoma cell lines. Biochem Biophys Res Commun. 2008; 
373:607–12. https://doi.org/10.1016/j.bbrc.2008.06.090. 
28. Saharinen P, Eklund L, Alitalo K. Therapeutic targeting of 
the angiopoietin-TIE pathway. Nat Rev Drug Discov. 2017; 
16:635–61. https://doi.org/10.1038/nrd.2016.278. 
29. Schulz P, Fischer C, Detjen KM, Rieke S, Hilfenhaus 
G, von Marschall Z, Böhmig M, Koch I, Kehrberger 
J, Hauff P, Thierauch KH, Alves F, Wiedenmann B, 
Scholz A. Angiopoietin-2 drives lymphatic metastasis of 
pancreatic cancer. FASEB J. 2011; 25:3325–35. https://doi.
org/10.1096/fj.11-182287. 
30. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel 
density in human solid tumours. Br J Cancer. 2002; 
86:1566–77. https://doi.org/10.1038/sj.bjc.6600315.
